ArticleJournal of medical virology2026
Tracking COVID-19 Severity and Progression Through Amines and Lipid Mediators.
Article in Journal of medical virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Coronavirus disease 2019 (COVID-19) exhibits a broad spectrum of severity, ranging from mild to critical cases. To reduce mortality and costs, tailored early interventions for at-risk patients are essential. This study elucidates the association between longitudinal metabolomic profiles and COVID-19 severity and progression. We analyzed metabolomic profiles from a subset of the BEAT-COVID cohort, a modestly sized yet well-characterized and longitudinally sampled COVID-19 cohort. The study comprises hospitalized patients sampled approximately twice weekly for up to 60 days after symptom onset during the first (29 patients, n = 92 samples) and second (48 patients, n = 112 samples) waves. Alongside sampling, daily disease severity was assessed using the Severity of Coronavirus Disease Assessment (SCODA) score. Associations were analyzed using univariate and multivariate linear mixed-effect models. Perturbations in the tryptophan-kynurenine pathway, linoleic acid derivatives, endocannabinoids, and sphingosines were significantly associated with disease severity and progression. These metabolic changes correlated with immune markers reflecting COVID-19 severity. Some observed potential differences between the two waves could be partially attributed to the influence of corticosteroid treatment introduced during the second wave. Once confirmed in an independent validation cohort, the identified oxidative stress- and inflammation-related metabolites may serve as biomarkers of disease progression, help identify at-risk hospitalized patients, and provide potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.